Month 6 – visit 2 | Month 12 – month 6 | |||||||
ELTGOL# | Placebo# | Mean difference (95% CI)¶ | p-value+ | ELTGOL# | Placebo# | Mean difference (95% CI)¶ | p-value+ | |
SGRQ total | −7.7±8.6 | 7.8±10.5 | −15.51 (−22.10; −8.92) | <0.001 | 0.8±14 | 1.6±9.6 | −0.78 (−9.07; 7.50) | 0.848 |
SGRQ symptoms | −8.3±21.4 | 6.2±10.3 | −14.50 (−26.11; −2.89) | 0.017 | −1±17.9 | 0.7±15.8 | −1.65 (−9.04; 9.54) | 0.775 |
SGRQ activity | −4.5±12 | 8.6±14.5 | −13.06 (−22.17; −3.95) | 0.006 | 0.4±14.4 | 2.5±15.8 | −2.10 (−12.46; 8.26) | 0.683 |
SGRQ impact | −9.3±10.5 | 7.9±13.2 | −17.23 (−25.40; −9.06) | <0.001 | 1.6±16.4 | 1.4±9.5 | 0.25 (−9.04; 9.54) | 0.957 |
LCQ total | 1.9±4 | −1.6±2.6 | 3.53 (1.20; 5.86) | 0.004 | 0.002±3.5 | −0.5±2.2 | 0.48 (−1.54; 2.50) | 0.633 |
#: values represent mean difference and standard deviations in score questionnaire between month 6 and visit 2 and between month 6 and month 12; ¶: values represent mean differences in the variable “difference in score questionnaire between month 6 and visit 2” and “difference in score questionnaire between month 12 and month 6” between groups (ELTGOL versus placebo) and their 95% confidence interval; +: unpaired t-test.